Practice-Changing Lung Cancer Data From WCLC and ESMO 2021 - Episode 3

Living In a Targeted Therapy Revolution of NSCLC

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, share insight on the data with novel targeted agents with impressive efficacy in patients with lung cancer, as seen at the 2021 ESMO Congress and the 2021 World Conference on Lung Cancer.

EP. 1: Adjuvant Immunotherapy Breakthroughs in Lung Cancer from ESMO 2021
EP. 2: Neoadjuvant and Stage IV Immunotherapy Data Shaking Up Lung Cancer Paradigm
Now Viewing
EP. 3: Living In a Targeted Therapy Revolution of NSCLC
EP. 4: It’s Not a Small World for Small Cell Lung Cancer Treatment

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, share insight on the data with novel targeted agents with impressive efficacy in patients with lung cancer, as seen at the 2021 ESMO Congress and the 2021 World Conference on Lung Cancer.

Related Content:

Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Sandra & Edward Meyer Cancer CenterColumbia University Herbert Irving Comprehensive Cancer CenterThoracic Night LiveLung Cancer
OncLive’s September Roundup of Key FDA Approvals in Oncology
Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC
Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLC